Navigation Links
Cancer drug effectiveness substantially advanced
Date:4/8/2010

Santa Barbara, Calif., April 8, 2010 Researchers have shown that a peptide (a chain of amino acids) called iRGD helps co-administered drugs penetrate deeply into tumor tissue. The peptide has been shown to substantially increase treatment efficacy against human breast, prostate and pancreatic cancers in mice, achieving the same therapeutic effect as a normal dose with one-third as much of the drug. In a transformative paper published today in the online edition of the journal Science, Erkki Ruoslahti, M.D., Ph.D., distinguished professor at Sanford-Burnham Medical Research Institute and founding member of the UC Santa Barbara-Sanford|Burnham Center for Nanomedicine, Kazuki N. Sugahara, M.D., Ph.D., Tambet Teesalu, Ph.D., and fellow researchers at the Center for Nanomedicine and the Cancer Center of Santa Barbara, announced this significant advance in cancer therapy.

"Drugs generally have difficulty penetrating tumors beyond a few cell diameters from a blood vessel," said Dr. Ruoslahti. "This leaves some tumor cells with a suboptimal dose, increasing the risk of both recurrence and drug resistance. The iRGD peptide solves this problem by activating a transport system in tumors that distributes co-injected drugs into the entire tumor and increases drug accumulation in the tumor."

Dr. Ruoslahti showed in the 1980s that a 3 amino-acid peptide motif (RGDArginine-Glycine-Aspartic Acid) serves as a highly selective identifier of malignant tissue, binding to unique re-ceptors in the vasculature of cancers. The RGD peptide's ability to home to tumors has been used to design new compounds for cancer diagnosis and treatment.

The new variant of RGD (iRGDinternalizing RGD) combines the RGD motif with a tissue penetration element called CendR. Like the earlier RGD peptides, iRGD homes to tumors, but exposure of the CendR motif when the iRGD is enzymatically cleaved activates a transport system through tumor blood vessel walls into the tumor core. In a paper published in Cancer Cell late last year, the research team showed that coupling iRGD to anti-cancer drugs allowed them to penetrate deep into tumors, effectively increasing the activity of the drugs.

The research reported in this latest Science paper adds a new and important twist to the story: The researchers made the unanticipated discovery that anti-cancer drugs do not need to be chemically attached to the iRGD peptide for iRGD to boost their efficacy. Simply co-administering iRGD with a drug enhances the drug's anti-cancer properties. Co-administration could be even more effective at delivering therapeutic agents inside tumors than conjugating the agents with the peptide. This new paradigm means that iRGD has the potential to enhance the efficacy of already approved drugs without creating new chemical entities, which would complicate the path to approval for clinical use.

In addition to being effective against human breast, prostate and pancreatic cancers grown in mice, iRGD can penetrate other tumor types and could possibly be used to treat most, if not all, solid tumors. The iRGD peptide was also shown to enhance the therapeutic effects of multiple types of anti-cancer drugs, including a small molecule drug, a monoclonal antibody and two nanoparticle drugs. Tumors essentially resistant to a particular drug showed good responses when the drug was combined with iRGD, and tumors partially responsive to another drug were eradicated by the combination.

"We are really excited about the potential of iRGD, and I'd like to thank my colleagues, Kazuki Sugahara and Tambet Teesalu in particular, who made this all happen," said Dr. Ruoslahti. "These results with human tumors in mice are very promising, but we still have to demonstrate the value of iRGD in treating cancers in humans."


'/>"/>

Contact: Josh Baxt
jbaxt@sanfordburnham.org
858-795-5236
Sanford-Burnham Medical Research Institute
Source:Eurekalert

Related biology news :

1. Disparities persist in outcomes for African-American women with advanced breast cancer
2. The immune systems guard against cancer
3. Chip checks for oral cancer
4. New discovery is a significant boost to cancer research
5. VARI study could improve treatments for prostate cancer
6. New cancer therapy may fight cardiovascular disease
7. Cancer therapy using unique imaging, delivery system focus of NSF CAREER Award
8. Advances reported in quest for drugs targeting childhood cancer
9. Development of new anti-cancer gene therapy approach using lentiviral vectors
10. Specific lymph node radiotherapy is well-tolerated after surgery in early breast cancer patients
11. New way discovered to predict which breast cancer patients should be treated with anthracyclines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2016)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce the attainment of record-setting ... result of the company,s laser focus on (and growing ... it,s comprehensive, easy-to-use and highly affordable cloud-based technology platform. ... MedNet growth achievements in 2015 include: , ...
(Date:1/15/2016)... JUAN, Puerto Rico , Jan. 15, 2016 /PRNewswire/ ... companies big and small to find new ways to ... driven culture. iOS and Android ... device based on biometrics, transforming it into a hardware ... request that users swipe their fingerprint on their KodeKey ...
(Date:1/11/2016)... , Jan. 11, 2016 Synaptics Incorporated ... interface solutions, today announced that its ClearPad ® ... (TDDI) products won two separate categories in the 8 ... Innovator and Best Technology Breakthrough. The Synaptics ® ... a simplified supply chain, thinner devices, brighter displays and ...
Breaking Biology News(10 mins):
(Date:2/9/2016)... ... February 08, 2016 , ... ... services, announced today the launch of its revamped and improved website. In an ... service solutions, the redesigned website will better communicate how the company designs and ...
(Date:2/9/2016)... ... February 09, 2016 , ... The publishing industry has ... publishing is one of the popular publication models that has received wider acknowledgement ... and 3000+ International Conferences across the globe, OMICS International is all ...
(Date:2/9/2016)... LONDON , February 9, 2016 ... replace paper and protect IP   E-WorkBook ... will be rolled out in Germany ... and protect valuable IP. Users will be able to search ... or experiment as part of the application, to boost collaboration ...
(Date:2/8/2016)... , Feb. 8, 2016 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... top ten finalists for clean technology companies in the TSX ... top 10 companies listed on the TSX Venture Exchange, in ... gas, clean technology & life sciences, diversified industries ... weighting given to return on investment, market cap growth, trading ...
Breaking Biology Technology: